Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II chemoradiotherapy with 5-fluorouracil, mitomycin C, and panitumumab for squamous cell carcinoma of the anal canal
2010-018430-48Phase 2Completed
- Sponsor
- GEMCAD
- Start
- Mar 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, fluorouracil and mitomycin c in anal squamous cell carcinoma (SCCA), sponsored by GEMCAD. Primary endpoint: 3-year disease-free survival rate. Started Mar 2010; status: completed.
02
Drugs
panitumumabfluorouracilmitomycin c
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2010-018430-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018430-48.